Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$9.6M
28M shares
52-week range
$0.32 – $7.19
2% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
2.59%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $1.1M |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | −$1.1M |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $3.6M | $15.9M | $25.4M | $34.6M | $51.8M | $55.8M | $60.5M |
| Operating income | −$4.7M | −$20.7M | −$36.8M | −$51.2M | −$68.9M | −$76.2M | −$80.5M |
| EBITDA | $0 | $0 | −$30.3M | −$36.7M | −$63.4M | −$69.9M | −$74.7M |
| Net income | −$5.0M | −$31.7M | −$30.6M | −$37.7M | −$64.5M | −$71.3M | −$75.8M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | 0.00 | -183.08 | -26.89 | -10.33 | -6.18 | -4.89 | -3.95 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-1.11 | $-1.11–$-1.11 | 2 |
| 2027 | $173800 | $-1.32 | $-2.12–$-0.49 | 3 |
| 2028 | $34M | $-0.84 | $-1.83–$-0.09 | 4 |
| 2029 | $17M | $-1.10 | $-1.10–$-1.10 | 2 |
Forward consensus · source: Financial Modeling Prep
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
www.jaspertherapeutics.comNo one on the platform currently holds JSPR.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 177,500 | $155.5K |
| Execution date | Ratio |
|---|---|
| 2024-01-04 | 1-for-10reverse |
No one on the platform has traded JSPR yet.
| $36M |
| — |
| MURAMural Oncology plc | $2.04 | +0.00% | $35M | — |
| NXTCNextCure, Inc. | $1.75 | +6.38% | $5M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$JSPR With the individuals serving as CEO, CFO, and directors, this company has tremendous potential to be sold or traded at a value far exceeding its current trading price. We can expect great news regarding JSPR soon.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.